Nereus Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011

Date: March 1, 2011
Pages: 56
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: N5063F6624BEN
Leaflet:

Download PDF Leaflet

Nereus Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Nereus Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Nereus Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Nereus Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Nereus Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Nereus Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Nereus Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Nereus Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Nereus Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Nereus Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Nereus Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Table of Contents
List of Tables
List of Figures
Nereus Pharmaceuticals, Inc. Snapshot
Nereus Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Nereus Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Nereus Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Nereus Pharmaceuticals, Inc. – Pipeline Products Glance
Nereus Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nereus Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Nereus Pharmaceuticals, Inc. – Drug Profiles
NPI-0052 + Zolinza
Product Description
Mechanism of Action
R&D Progress
Plinabulin + Docetaxel
Product Description
Mechanism of Action
R&D Progress
NPI 0052
Product Description
Mechanism of Action
R&D Progress
NPI-0052 + Velcade
Product Description
Mechanism of Action
R&D Progress
NPI-0052 + Zolinza
Product Description
Mechanism of Action
R&D Progress
Plinabulin
Product Description
Mechanism of Action
R&D Progress
NPI-0052 + Rev/Dex
Product Description
Mechanism of Action
R&D Progress
NPI-1342
Product Description
Mechanism of Action
R&D Progress
NPI-1387
Product Description
Mechanism of Action
R&D Progress
NPI-1390
Product Description
Mechanism of Action
R&D Progress
NPI-2358 + FOLFIRI
Product Description
Mechanism of Action
R&D Progress
NPI-3114
Product Description
R&D Progress
NPI-3304
Product Description
R&D Progress
Nereus Pharmaceuticals, Inc. – Pipeline Analysis
Nereus Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Nereus Pharmaceuticals, Inc. - Pipeline Products By Target
Nereus Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Nereus Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Nereus Pharmaceuticals, Inc. – Recent Pipeline Updates
Nereus Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jun 22, 2010: Nereus Completes Enrollment Of Phase II ADVANCE Clinical Trial Of Plinabulin In Non-Small Cell Lung Cancer
Nov 23, 2009: Nereus Pharmaceuticals Presents Positive Interim Data Of Phase 2 Clinical Trial Of Plinabulin (NPI-2358) In Non-Small Cell Lung Cancer
Mar 23, 2009: Nereus Pharmaceuticals Initiates Advance, A Randomized Phase 2 Clinical Trial Of NPI-2358 In Non-Small Cell Lung Cancers
Apr 18, 2008: Nereus Pharmaceuticals Initiates Combination Clinical Trial For Proteasome Inhibitor NPI-0052 In Solid Tumors
Apr 18, 2008: Nereus Pharmaceuticals Initiates Combination Clinical Trial For Proteasome Inhibitor NPI-0052 In Solid Tumors
Apr 18, 2008: Nereus Pharmaceuticals Initiates Combination Clinical Trial For Proteasome Inhibitor NPI-0052 In Solid Tumors
Mar 20, 2008: Nereus Pharmaceuticals Initiates Clinical Trial Of NPI-2358 In Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
Nov 26, 2007: Nereus Pharmaceuticals To Present Research At The Annual Meeting Of The American Society Of Hematology
Oct 16, 2007: Nereus Pharmaceuticals, Inc.'s NPI-0052 Named One of the Industry's Top Ten Unpartnered Oncology Drug Candidates
Apr 16, 2007: The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma
Financial Deals Landscape
Nereus Pharmaceuticals, Inc., Deals Summary, 2004 to 2011
Nereus Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Nereus Pharmaceuticals Secures $45 Million In Series D-2 Financing
Nereus Pharmaceuticals Secures $18.3 Million In Final Tranche Of Series D Financing
Nereus Pharmaceuticals Secures $24.3 Million In First Tranche Of Series D Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Nereus Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Nereus Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Nereus Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Nereus Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2011
Nereus Pharmaceuticals, Inc. - Phase II, 2011
Nereus Pharmaceuticals, Inc. - Phase I, 2011
Nereus Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2011
Nereus Pharmaceuticals, Inc. - Pipeline By Target, 2011
Nereus Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Nereus Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011
Nereus Pharmaceuticals, Inc. – Recent Pipeline Updates, 2011
Nereus Pharmaceuticals, Inc., Deals Summary, 2004 to 2011

LIST OF FIGURES

Nereus Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Nereus Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Nereus Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Nereus Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2011
Nereus Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2011
Nereus Pharmaceuticals, Inc. - Pipeline By Target, 2011
Nereus Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Nereus Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011

Ask Your Question

Nereus Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: